XML 19 R8.htm IDEA: XBRL DOCUMENT
v3.24.1.u1

Development-Stage Risks and Liquidity | 3 Months Ended
--- | ---
Mar. 31, 2024
Development-Stage Risks and Liquidity |
Development-Stage Risks and Liquidity | Development-Stage Risks and Liquidity The accompanying unaudited interim consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has incurred losses and negative cash flows from operations since inception and has an accumulated deficit of $264.1 million as of March 31, 2024. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales from its product candidates currently in development. As of March 31, 2024, the Company had $56.5 million in cash and cash equivalents. Absent any other action, the Company would have required additional liquidity to continue its operations over the next 12 months, which would have raised substantial doubt about its ability to continue as a going concern. As discussed in Note 1, in late March 2024, the Company and its board of directors approved a revised operating plan that suspends certain development programs, reduces its workforce and decreases other non-essential activities to extend the Company’s cash runway. The Company projects this revised operating plan will alleviate the substantial doubt that has been raised by significantly decreasing expenses, thereby reducing ongoing liquidity needs to enable the continuation of operations for at least 12 months from the issuance date of these unaudited interim consolidated financial statements. The Company is subject to those risks associated with any specialty biotechnology company that has substantial expenditures for research and development. There can be no assurance that the Company’s research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants.

X
- References No definition available. + Details
Name: | carm_DevelopmentStageRisksAndLiquidityAbstract
Namespace Prefix: | carm_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure on risks of development-stage and liquidity. + References No definition available. + Details
Name: | carm_DevelopmentStageRisksAndLiquidityTableTextBlock
Namespace Prefix: | carm_
Data Type: | dtr-types1:textBlockItemType
Balance Type: | na
Period Type: | duration